Latest news

Thumbnail image for Santhera’s Raxone fails in MS trial

Santhera’s Raxone fails in MS trial

Santhera has been hit with more bad news regarding its flagship mitochondrial disease therapy idebenone, after it failed to hit targets in a trial assessing its potential in multiple sclerosis.

6th March 2018

Thumbnail image for Artios in-licenses experimental cancer drug

Artios in-licenses experimental cancer drug

Cambridge, UK-based Artios Pharma has exercised an option to in-license the first nuclease drug development programme from its research alliance with Masaryk University in the Czech Republic.

6th March 2018

Thumbnail image for UK PM signals intent to remain with EMA

UK PM signals intent to remain with EMA

Prime Minister Theresa May has unveiled the government’s desire for the UK to remain part of the European Medicines Agency following its departure from the European Union.

5th March 2018

Thumbnail image for Biogen, AbbVie pull MS drug from the market

Biogen, AbbVie pull MS drug from the market

European regulators have started an “urgent review” of Biogen and Abbvie’s multiple sclerosis therapy Zinbryta following a stream of cases of serious inflammatory brain disorders in patients taking the drug.

5th March 2018

Thumbnail image for Sanofi files Dupixent for severe asthma

Sanofi files Dupixent for severe asthma

US regulators have accepted for review Sanofi/Regeneron’s biologic Dupixent as an add-on maintenance treatment in certain adults and adolescents with moderate-to-severe asthma.

2nd March 2018

Previous  --   7 8 9 10 11 12 13 14 15 16   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download